Cytokinetics Reports Fourth Quarter 2025 Financial Results and Provides Business Update

MYQORZO® Approved for Adults with Symptomatic Obstructive HCM in U.S., China and Europe; U.S. Launch Underway with First Prescriptions Dispensed within Days of Drug Availability Supplemental NDA for MAPLE-HCM Submitted to FDA in Q1 2026 Expect to Share Topline Results from ACACIA-HCM in Q2 2026 Company Provides 2026 Financial Guidance;~$1.2 Billion in Cash, Cash Equivalents and Investments as of December 31, 2025 SOUTH SAN FRANCISCO, Calif., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasd ...